De Novo Genome Assembly Market Report 2026

De Novo Genome Assembly Market Overview

• De Novo Genome Assembly market size has reached to $1.99 billion in 2025 • Expected to grow to $3.96 billion in 2030 at a compound annual growth rate (CAGR) of 14.8% • Growth Driver: Growing Demand For Personalized Medicine Driving The Market Growth Due To Increasing Rare Disease Awareness • Market Trend: Innovative Solutions Driving Faster And More Accurate Genome Assemblies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under De Novo Genome Assembly Market?

De novo genome assembly is the process of reconstructing a complete genome sequence from short DNA fragments without using a reference genome. It relies on overlapping regions between fragments to accurately piece together the original genomic sequence. It is essential for studying organisms with unknown or highly variable genomes. The main components of de novo genome assembly include software and services. Software refers to bioinformatics tools that reconstruct genomes from sequencing data without relying on a reference genome, enabling analysis of novel or poorly characterized organisms. They are used for organism types including human, animal, plant, microbial, and metagenomic or mixed samples, and utilize technologies such as next-generation sequencing, third-generation sequencing, Sanger sequencing, and other technologies. The various applications involved are clinical diagnostics, agricultural genomics, environmental genomics, evolutionary biology, and other applications, and they are used by several end users such as academic and research institutes, pharmaceutical and biotechnology companies, hospitals and clinics, and other end-users.

What Is The De Novo Genome Assembly Market Growth Forecast?

The de novo genome assembly market size is expected to see rapid growth in the next few years. It will grow to $3.96 billion in 2030 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to integration of ai in genome assembly, expansion of cloud-based bioinformatics platforms, demand for rapid custom genome sequencing, growth in precision medicine applications, investment in evolutionary and environmental genomics. Major trends in the forecast period include automated genome assembly pipelines, cloud-based data analysis, high-throughput sequencing integration, custom bioinformatics services, visualization & annotation enhancements.

What Is The Driver Of The De Novo Genome Assembly Market?

The growing demand for personalized medicine is expected to propel the growth of the de novo genome assembly market going forward. Personalized medicine refers to medical treatments and therapies tailored to individual patients based on their genetic makeup, biomarkers, and specific disease characteristics. The demand for personalized medicine is rising due to advances in genomic technologies and molecular diagnostics, which enable treatments to be customized based on an individual’s genetic profile, improving outcomes and minimizing side effects. De novo genome assembly advances personalized medicine by reconstructing an individual’s genome from scratch, enabling the discovery of unique genetic variants and structural alterations that inform precision therapies, tailored drug selection, and early disease intervention. For instance, in February 2024, Personalized Medicine Coalition, a US-based non-profit organization, the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022, including seven cancer drugs and three for other diseases and conditions. Therefore, the growing demand for personalized medicine is driving the growth of the de novo genome assembly industry.

Key Players In The Global De Novo Genome Assembly Market

Major companies operating in the de novo genome assembly market are Thermo Fisher Scientific Inc., Eurofins Scientific SE, Illumina Inc., QIAGEN N.V., Novogene Corporation, Oxford Nanopore Technologies Ltd., Pacific Biosciences of California Inc., Medgenome labs pvt. Ltd, DNASTAR Inc., Nucleome Informatics Pvt Ltd, Seven Bridges Genomics, DNAnexus Inc., Strand Life Sciences Pvt. Ltd., BaseClear B.V., Dovetail Genomics LLC, SoftGenetics LLC, CosmosID Inc., Microba Life Sciences Ltd., GenomeScan B.V., BGI Genomics Co. Ltd., Macrogen Inc., SeqMatic LLC, NeuGen Biologicals.

Global De Novo Genome Assembly Market Trends and Insights

Major companies operating in the de novo genome assembly market are focusing on developing innovative solutions such as, high-throughput genome assembly platforms to accelerate genome reconstruction and improve accuracy for complex and diverse organisms. High-throughput genome assembly platforms are advanced systems that combine long- and short-read sequencing data to rapidly reconstruct complete genomes with high accuracy, helping researchers generate contiguous assemblies faster and handle complex or repetitive genomic regions more efficiently than traditional methods. For instance, in May 2024, Dovetail Genomics Inc., a US-based genomics technology company, launched the AssemblyLINK Assay, a high-throughput genome assembly platform designed to accelerate genome assembly workflows and enhance the accuracy of de novo assemblies. The AssemblyLINK Assay integrates proprietary scaffolding technology with existing sequencing data to generate highly contiguous genome assemblies, simplifies data processing through streamlined computational pipelines, and supports a wide range of organisms, from plants and animals to microbial communities. Its unique features include compatibility with multiple sequencing platforms, reduction in manual intervention, and optimized performance for complex and large genomes, making it particularly valuable for biodiversity research and conservation genomics.

What Are Latest Mergers And Acquisitions In The De Novo Genome Assembly Market?

In May 2024, MedGenome Labs Pvt. Ltd., an India-based genomics and molecular diagnostics company that specializes in providing de novo genome assembly services, partnered with Pacific Biosciences of California Inc. (PacBio) to support researchers in generating high-quality reference genomes and advancing genomic research. With this partnership, MedGenome Labs Pvt. Ltd. and PacBio aim to support researchers in generating high-quality reference genomes, advancing multiomics research, enabling comprehensive analysis of complex genomic regions, facilitating discovery of novel genes and regulatory elements, and accelerating the development of precision medicine and biotechnological applications. Pacific Biosciences of California Inc. is a US-based company specializing in long-read DNA sequencing and genomic analysis platforms.

What Defines the De Novo Genome Assembly Market?

The de novo genome assembly market includes revenues earned by entities by service such as genome assembly sequencing, bioinformatics analysis, genome annotation, custom genome assembly, comparative genomics analysis, structural variant analysis, metagenome assembly, microbial genome assembly, plant genome assembly and animal genome assembly. The market value includes the value of related goods sold by the service provider or included within the service offering. The de novo genome assembly market also includes sales of sequencing instruments, library preparation kits, reagents, flow cells, sequencing chips, sample preparation systems, high performance computing servers, storage systems, genome assembly software packages. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data And Analysis Are Included In The De Novo Genome Assembly Market Report 2026?

The de novo genome assembly market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the de novo genome assembly industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.